Database / Petrelintide
Petrelintide
No brand yet · Zealand Pharma / Roche. The gentlest profile in the pipeline: nausea in 1 in 5 and almost nobody quitting. Weight loss is about half of the strongest drugs.
Average weight loss
10.7%
Stopped for side effects
1%
Trial length
42 wk
Ranking score
n/r
ZUPREME-1 results
Phase 2 · 42 weeks · Up to 9 mg weekly
Adults with obesity, no diabetes (n=493)
Weight loss
10.7%
Nausea
20.0%
Vomiting
3.0%
Diarrhea
7.0%
Constipation
7.0%
Quit due to side effects
1.0%
n/r = not reported. Placebo group: 1.7%.
Worth knowing
- Week 42 result is exploratory; the primary 28-week result was 7.9 to 9.8%.
- Discontinuation shown is for stomach side effects only.
Next catalysts
H2 2026 Petrelintide Phase 3 program starts (Company guidance)
–
Not yet ranked
Needs Phase 3 data. We rank only drugs with a completed Phase 3 trial and published side-effect rates.
At a glance
- Company
- Zealand Pharma / Roche
- Targets
- Amylin
- Molecule
- Peptide
- Dosing
- Injection, weekly
- Status
- Phase 3 starting
Sources
History
- Petrelintide ZUPREME-1 published in The Lancet: up to 10.7% weight loss at 42 weeks.